Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders
AssigneeHoffmann-La Roche Inc.
InventorPatrick Nef
Life of this patent
Estimating the term…
Abstract
Provided is a method for determining whether an agent is an agonist of the neuron-specific calcium sensor-1 (NCS-1), for consideration of an agonist of NCS-1 as a drug candidate for therapy of a behavioral disorder or for improving learning and/or memory of a subject, said method comprising the steps of: (a) contacting a cell, tissue or non-human animal with an agent to be screened under conditions to permit neuron-specific calcium sensor-1 (NCS-1) activity; and (b) determining NCS-1 activity of said treated cell, tissue or non-human animal, wherein an increase in NCS-1 activity compared with a corresponding control cell, tissue or animal is indicative of an agent which is an agonist of NCS-1.
Claims11
A method for determining whether an agent is an agonist of the neuron-specific calcium sensor-1 (NCS-1), for consideration of an agonist of NCS-1 as a drug candidate for therapy of a behavioral disorder or for improving learning and/or memory of a subject, said method comprising the steps of:
- (a) contacting a cell, tissue or non-human animal with an agent to be screened under conditions to permit neuron-specific calcium sensor-1 (NCS-1) activity;
- and
- (b) determining NCS-1 activity of said treated cell, tissue or non-human animal, wherein an increase in NCS-1 activity compared with a corresponding control cell, tissue or animal is indicative of an agent which is an agonist of NCS-1.
A transgenic non-human animal or a transgenic cell or tissue thereof, wherein said transgenic non-human animal displays a substantially reduced level of NCS-1 activity compared to the corresponding wild type animal, and comprises at least one mutant allele of the NCS-1 encoding gene.
A method for determining whether a patient has a CNS disorder or is at risk for developing a CNS disorder, comprising:
- determining the presence or absence of a mutation in the polynucleotide encoding neuron-specific calcium sensor-1 (NCS-1) in a biological sample from the patient,
- wherein the presence of said mutation indicates that the patient has a CNS disorder or is at risk for developing a CNS disorder.
A method for determining whether a patient has a CNS disorder or is at risk for developing a CNS disorder, comprising:
- (a) determining the concentration of a neuron-specific calcium sensor-1 (NCS-1) polypeptide in a biological sample from a patient;
- and
- (b) determining whether NCS-1 in the sample is present in a concentration lower than that in a control sample, wherein a lower concentration of NCS-1 as compared to control indicates the patient has a CNS disorder or is at risk for developing a CNS disorder.
Dependencies are inferred from the claim text.